Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
Research Square|August 13, 2025
ShinyEvents: harmonizing longitudinal data for real world survival estimationAlyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
NPJ Precision Oncology|January 12, 2026
ShinyEvents: harmonizing longitudinal data for real-world survival estimationAlyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
Cells|December 17, 2024
Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to ImmunotherapyIslam Eljilany, Sam Coleman, Aik Choon Tan, et al.
Research Square|February 6, 2026
Intrinsic tumor factors and extrinsic environmental and social exposures contribute to endometrial cancer recurrence patternsJesus Gonzalez Bosquet, Oyomoare Osazuwa-Peters, Vincent M Wagner, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 26, 2018
Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical NeviShawn Tahata, Shivendra V Singh, Yan Lin, et al.
Journal for Immunotherapy of Cancer|May 8, 2021
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysisAhmad A Tarhini, Ni Kang, Sandra J Lee, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitorsCaroline E Wheeler, Samuel S Coleman, Rebecca Hoyd, et al.
Journal for Immunotherapy of Cancer|June 23, 2025
Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committeeJennifer Dent, Micaella Jorge, Nora Sobrevilla, et al.
Nature Medicine|September 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trialGeorgina V Long, Nitya Nair, Daniel Marbach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2017
Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)Sanjiv S Agarwala, Sandra J Lee, Waiki Yip, et al.
Pageof 18